Atezolizumab for First-Line Treatment of PD-L1–Selected …
2020年9月30日 · IMpower110 is a global, randomized, open-label, phase 3 trial designed to evaluate the efficacy and safety of atezolizumab as compared with platinum-based …
Updated Overall Survival Analysis From IMpower110 ... - PubMed
Introduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative …
Updated Overall Survival Analysis From IMpower110: …
2021年4月27日 · IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative …
IMpower110 is a global, randomized, open-label, phase 3 trial designed to evaluate the efficacy and safety of atezolizumab as compared with platinum-based chemotherapy in...
WCLC丨终于等到了！5年、3年OS发布——详解IMpower110、KEY…
2021年1月29日 · KEYNOTE-010纳入1024例PD-L1肿瘤比例评分 (TPS)≥1%的经治晚期非小细胞肺癌（NSCLC）患者，随机1:1:1接受Pembrolizumab (帕博利珠单抗)2 mg/kg q3w、10 …
IMpower110: Interim overall survival (OS) analysis of a phase III …
2019年10月1日 · IMpower110 evaluated atezo as 1L tx in PD-L1–selected pts independent of tumour histology. IMpower110 enrolled 572 chemo-naive pts with stage IV nonsquamous …
Updated Overall Survival Analysis From IMpower110
2021年11月1日 · IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative …
全文编译丨III期IMpower-110研究：PD-L1一线治疗PD-L1高表达N…
IMpower-110旨在探索Atezolizumab较化疗一线治疗PD-L1选择的晚期非小细胞肺癌患者的疗效及安全性。 本次报道了基于中期分析的主要研究结果。 研究方法. IMpower-110是一项全球、多 …
IMpower 110中期分析：单药免疫治疗在PD-L1高表达晚期NSCLC治疗中的地位进一步确认
IMpower 110是一项III期、开放性、随机对照、全球多中心临床试验，对比了阿特珠单抗和标准化疗一线治疗经PD-L1筛选的572例IV期NSCLC患者。 主要研究终点为总生存期（OS），次要 …
Atezolizumab for First-Line Treatment of PD-L1-Selected ... - PubMed
2020年10月1日 · Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non …